Maravai LifeSciences Holdings, Inc.
Symbool: MRVI
NASDAQ
8.87
USDMarktprijs vandaag
-9.7422
Koers/Winst Verhouding
-0.1333
Koers/Winst Groei Verhouding
1.18B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Maravai LifeSciences Holdings, Inc. (MRVI) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2363.02 | 575 | 632.1 | 551.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 211.03 | 55.7 | 146.8 | 117.5 | ||||||
balance-sheet.row.inventory | 202.76 | 51.4 | 43.2 | 51.6 | ||||||
balance-sheet.row.other-current-assets | 88.79 | 17.8 | 25.8 | 19.7 | ||||||
balance-sheet.row.total-current-assets | 2865.6 | 699.9 | 847.9 | 740 | ||||||
balance-sheet.row.property-plant-equipment-net | 733.42 | 222.6 | 116.6 | 46.3 | ||||||
balance-sheet.row.goodwill | 1305.09 | 326 | 283.7 | 152.8 | ||||||
balance-sheet.row.intangible-assets | 925.15 | 221 | 216.7 | 117.6 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 2230.23 | 547 | 500.3 | 270.3 | ||||||
balance-sheet.row.long-term-investments | 45.8 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.tax-assets | 2531.2 | 0 | 765.8 | 808.1 | ||||||
balance-sheet.row.other-non-current-assets | -71.44 | 9.3 | 40.3 | 52.9 | ||||||
balance-sheet.row.total-non-current-assets | 5469.23 | 787.5 | 1434.4 | 1178.2 | ||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-assets | 8334.83 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.account-payables | 31.59 | 10.7 | 6 | 8.2 | ||||||
balance-sheet.row.short-term-debt | 51.39 | 12.9 | 11.7 | 9.7 | ||||||
balance-sheet.row.tax-payables | 2.07 | 1 | 1 | 1.4 | ||||||
balance-sheet.row.long-term-debt-total | 2246.36 | 518.7 | 573.6 | 524.6 | ||||||
Deferred Revenue Non Current | 829.37 | 79.4 | 0 | 0 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 30.27 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 272.13 | 60.5 | 89.4 | 65.7 | ||||||
balance-sheet.row.total-non-current-liabilities | 4488.85 | 610.1 | 1266.9 | 1279.1 | ||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.capital-lease-obligations | 342.6 | 79.4 | 57.8 | 3.7 | ||||||
balance-sheet.row.total-liab | 4854.39 | 697.6 | 1377.1 | 1372.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 10.04 | 2.5 | 2.6 | 2.6 | ||||||
balance-sheet.row.retained-earnings | 1480.29 | 285.7 | 404.8 | 184.6 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.other-total-stockholders-equity | 487.8 | 128.5 | 137.9 | 128.4 | ||||||
balance-sheet.row.total-stockholders-equity | 1978.13 | 416.8 | 545.2 | 315.5 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 8334.83 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.minority-interest | 1502.31 | 373.1 | 360 | 229.9 | ||||||
balance-sheet.row.total-equity | 3480.44 | 789.9 | 905.2 | 545.4 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 8334.83 | - | - | - | ||||||
Total Investments | 45.8 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.total-debt | 2459.18 | 611 | 585.3 | 534.3 | ||||||
balance-sheet.row.net-debt | 96.17 | 36 | -46.9 | -17 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -125.71 | -119 | 490.7 | 469.3 | ||||||
cash-flows.row.depreciation-and-amortization | 48.78 | 48.8 | 38.1 | 24.8 | ||||||
cash-flows.row.deferred-income-tax | 754.94 | 754.9 | 42.3 | 46.9 | ||||||
cash-flows.row.stock-based-compensation | 34.59 | 34.6 | 18.7 | 10.5 | ||||||
cash-flows.row.change-in-working-capital | 97.84 | 97.8 | -45.1 | -176.6 | ||||||
cash-flows.row.account-receivables | 84.39 | 84.4 | -22.3 | -70.4 | ||||||
cash-flows.row.inventory | 0.65 | 0.6 | 9.5 | -21.6 | ||||||
cash-flows.row.account-payables | 5.28 | 5.3 | -1.6 | 0.7 | ||||||
cash-flows.row.other-working-capital | 7.52 | 7.5 | -30.7 | -85.3 | ||||||
cash-flows.row.other-non-cash-items | -684.22 | -690.9 | -8.7 | -6.2 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 126.22 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -65.55 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.acquisitions-net | -69.62 | -69.6 | -238.3 | 120 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | 12.87 | 12.9 | -12.2 | 0.5 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -122.31 | -122.3 | -267.6 | 105.7 | ||||||
cash-flows.row.debt-repayment | -5.77 | -5.8 | -13.9 | -6 | ||||||
cash-flows.row.common-stock-issued | -0.35 | 0 | 2.4 | 1.7 | ||||||
cash-flows.row.common-stock-repurchased | -0.68 | 0 | 0 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-financing-activites | -54.3 | -55.3 | -176 | -154.8 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -61.09 | -61.1 | -187.5 | -159 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 1.6 | 0 | -0.1 | ||||||
cash-flows.row.net-change-in-cash | -57.18 | -57.2 | 80.9 | 315.1 | ||||||
cash-flows.row.cash-at-end-of-period | 2363.02 | 575 | 632.1 | 551.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 2420.19 | 632.1 | 551.3 | 236.2 | ||||||
cash-flows.row.operating-cash-flow | 126.22 | 126.2 | 536 | 368.6 | ||||||
cash-flows.row.capital-expenditure | -65.55 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.free-cash-flow | 60.67 | 60.7 | 518.9 | 353.7 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 288.94 | 288.9 | 883 | 799.2 | ||||||
income-statement-row.row.cost-of-revenue | 149.34 | 151.3 | 169 | 140.6 | ||||||
income-statement-row.row.gross-profit | 139.6 | 137.6 | 714 | 658.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 17.28 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.other-expenses | -1.34 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.operating-expenses | 163.82 | 141.8 | 147.6 | 115.3 | ||||||
income-statement-row.row.cost-and-expenses | 313.16 | 293.1 | 316.6 | 255.8 | ||||||
income-statement-row.row.interest-income | 27.73 | 27.7 | 2.3 | 30.3 | ||||||
income-statement-row.row.interest-expense | 45.89 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | 651.08 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | -1.34 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.total-operating-expenses | 651.08 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.interest-expense | 45.89 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.depreciation-and-amortization | 36.63 | 48.8 | -5.8 | -11 | ||||||
income-statement-row.row.ebitda-caps | 7.65 | - | - | - | ||||||
income-statement-row.row.operating-income | -28.98 | -4.2 | 574.2 | 554.6 | ||||||
income-statement-row.row.income-before-tax | 617.74 | 617.7 | 551.5 | 530.8 | ||||||
income-statement-row.row.income-tax-expense | 756.11 | 756.1 | 60.8 | 61.5 | ||||||
income-statement-row.row.net-income | -120.31 | -119 | 490.7 | 469.3 |
Vaak gestelde vragen
Wat is Maravai LifeSciences Holdings, Inc. (MRVI) totale activa?
Maravai LifeSciences Holdings, Inc. (MRVI) totale activa is 1487450000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 141006000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.483.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.416.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.100.
Wat is Maravai LifeSciences Holdings, Inc. (MRVI) nettowinst (netto-inkomen)?
De nettowinst is -119029000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 610967000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 141799000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 574962000.000.